# Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

> **NCT01868269** · PHASE3 · COMPLETED · sponsor: **Institut Curie** · enrollment: 102 (actual)

## Conditions studied

- Opsoclonus Myoclonus Syndrome
- Neuroblastoma

## Interventions

- **DRUG:** Dexamethasone acetate
- **DRUG:** dexamethasone and cyclophosphamide
- **DRUG:** dexamethasone and rituximab

## Key facts

- **NCT ID:** NCT01868269
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-18
- **Primary completion:** 2021-05-09
- **Final completion:** 2025-01-17
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868269, "Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01868269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*